इस प्रकरण का ऑडियो तोड़ा जा सकता है।
How to fix it?
इस एपिसोड के बारे में
Listen to Tina Wang, Statistician, and Dr. Paul Schuette, Deputy Division Director, in the Office of Biostatistics Division of Analytics and Informatics within FDA’s Center for Drug Evaluation and Research discuss FDA’s experiences with a centralized statistical monitoring tool.
अंग्रेज़ी
संयुक्त राज्य अमरीका
पिछले एपिसोड्स खोजें
FDA CDER Small Business and Industry Assistance (SBIA) Chronicles के पिछले एपिसोड खोजें।
इस पॉडकास्ट के अन्य एपिसोड
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
अस्वीकरण: इस पृष्ठ पर एम्बेडेड पॉडकास्ट और कलाकृति U.S. Food and Drug Administration, Center for Drug Evaluation and Research से हैं, जो इसके मालिक की संपत्ति है और Listen Notes, Inc. से संबद्ध या समर्थित नहीं है।
संपादित करें
पॉडकास्ट डेटाबेस को अपडेटेड रखने में मदद के लिए धन्यवाद।
